Systemic treatment with pulsed electromagnetic fields do not affect bone microarchitecture in osteoporotic rats by Jagt, O.P. (Olav) van der et al.
ORIGINAL PAPER
Systemic treatment with pulsed electromagnetic fields
do not affect bone microarchitecture in osteoporotic rats
Olav P. van der Jagt & Jacqueline C. van der Linden &
Jan H. Waarsing & Jan A. N. Verhaar & Harrie Weinans
Received: 25 November 2011 /Accepted: 19 December 2011 /Published online: 17 January 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Purpose Pulsed electromagnetic fields (PEMF) are currently
used in the treatment of spinal fusions and non-unions. There
are indications that PEMF might also be effective in the
treatment of osteoporosis. In this study we examined whether
whole-body PEMF treatment affects the bone microarchitec-
ture in an osteoporotic rat model.
Methods Twenty-week-old female rats were ovariectomised
(n020). Four different PEMF treatment protocols based on
previous experimental studies and based on clinically used
PEMF signals were examined (2 h/day, 5 days/week). A con-
trol group did not receive PEMF. At zero, three and six weeks
cancellous and cortical bone architectural changes at the prox-
imal tibia were evaluated using in vivo microCT scanning.
Results PEMF treatment did not induce any changes in
cancellous or cortical bone compared to untreated controls.
Conclusions Although previous studies have shown strong
effects of PEMF in osteoporosis we were unable to demon-
strate this in any of the treatment protocols. Using in vivo
microCT scanning we were able to identify small bone
changes in time. Subtle differences in the experimental set-
up might explain the differences in study outcomes in the
literature. Since PEMF treatment is safe, future experimental
studies on the effect of PEMF on bone can better be per-
formed directly on humans, eliminating the potential trans-
lation issues between animals and humans. In this study we
found no support for the use of PEMF in the treatment of
osteoporosis.
Introduction
Osteoporosis is a disease characterised by progressive bone
loss and deterioration of the microarchitecture leading to an
increased fracture risk. Osteoporosis can have distinctive
causes including lack of sex hormones, long-term use of
glucocorticoids or disuse. Current standard therapy consists
of reducing further bone loss using bisphosphonates [1].
The use of bisphosphonates is accompanied by potential
side effects such as gastrointestinal complaints, osteonecro-
sis of the jaw and atypical femoral fractures [2]. As an
alternative treatment biophysical stimuli have long been
proposed. These might be cheaper and induce fewer side
effects. Pulsed electromagnetic fields (PEMF) might be one
such treatment and indeed there is some evidence that these
positively influence bone mass.
The finding that electrical currents are induced during
mechanical loading of bone has led to the development of
PEMF [3, 4]. Much research has been done on the effects of
PEMF on bone. In vitro studies do show that a variety of
growth factors that are important in bone metabolism are
affected, including bone morphogenetic protein 2 (BMP-2),
transforming growth factor beta (TGF-β) and insulin-like
growth factor II (IGF-II) [5–11]. Furthermore, PEMF result
in the activation of extracellular signal-regulated kinase
(ERK), mitogen-activated protein kinase (MAPK) and pros-
taglandin synthesis, which might also lead to stimulatory
effects on bone [12–14]. Clinically PEMF are widely used
for the treatment of non-unions, although they have never
been proven to be effective in a prospective randomised
controlled trial [15–22].
PEMF as treatment for osteoporosis have been studied
before. In a clinical study it was shown that PEMF treatment
of the wrist induced an increase in bone mineral density
(BMD) in the distal radius of osteoporosis-prone women
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[23]. Re-examination 12 years later did show that these
effects had lapsed [24]. Only a few animal studies have been
published on the subject. In one study complete preventive
effects of PEMF on trabecular bone loss in an ovariectomised
rat model were demonstrated [12]. PEMF consisted of a single
pulse wave form with a maximum of 8 G and were applied
eight hours per day. In another study it was shown that PEMF
led to trabecular thickening in ovariectomised rats when
treated with pulse bursts with a maximum of 9.6 G for
six hours per day [25]. In a third study electromagnetic fields
(EMF) induced pronounced cortical bone formation [26].
EMF consisted of a sinusoid wave form with a maximum
electromagnetic field of 10 G and were applied for four hours
per day. One study using osteoporotic rats did not demonstrate
a beneficial effect on bonemass when treated with PEMFwith
15 G for 24 hours per day [27]. Furthermore, PEMF have also
been shown to influence bone mass in disuse osteoporosis
both clinically and experimentally [28–30].
Because treatment of osteoporosis with PEMF can have
important consequences for today’s standard treatment, we
examined the effect of whole-body PEMF treatment on the
bone microarchitecture in a rat model of osteoporosis. Cancel-
lous and cortical bone changes in the proximal tibia were
followed over time using in vivo microCT scanning.
Methods
Twenty female Wistar WU rats were obtained (Charles River,
The Netherlands). All animals were housed in pairs in the
institute’s animal facility with a 12-hour light/dark regimen
and received standard food pellets and water ad libitum. The
study protocol was approved by the local Animal Experiments
Committee (EUR 415) and was in accordance with Dutch law
on animal experimentation.
At an age of 20 weeks a bilateral ovariectomy (OVX) was
performed under sterile conditions to simulate osteoporosis.
This was done under 3% isoflurane gas anaesthesia (Rhodia
Organique Fine Ltd., Bristol, UK). Buprenorphine 0.05mg/kg
per 12 hours (Schering-Plough, Kenilworth, NJ, USA) was
given for pain relief for three days post-operatively.
The second day after OVX, PEMF treatment was started
for five days/week over a period of six weeks. During treat-
ment the animals were placed in a cage (24×30×12 cm) in
pairs, with food and water ad libitum. The cage was sur-
rounded by two connected coils normally used in the treat-
ment of non-unions of the femur (IMD, Uden, The
Netherlands) (Fig. 1). The rats were divided into five groups
of four animals/group. The sample size was chosen for
logistical reasons and not on the basis of a power analysis.
The group sizes were kept relatively small because in vivo
microCT analysis can accurately measure small changes
over in time. A custom-made generator produced the
electromagnetic signals (see details below). The first group
served as controls and was placed in a cage covered with
non-functioning coils for two hours per day.
The second group was treated with a commercially avail-
able PEMF device that is effective for the treatment of non-
unions and is clinically used (Orthopulse®, IMD, Uden, The
Netherlands) [31]. The device produces PEMF with a 1-G
electromagnetic field, consisting of 5-ms pulse bursts with 5-μs
pulses, and the bursts repeat at 15 Hz. Rats were treated
for two hours per day.
The treatment protocols of the third and fourth groups were
designed to investigate whether a non-continuous PEMF stim-
ulus would be more effective than a continuous stimulus,
similar to studies investigating the effects of mechanical vi-
bration on bone mass [32–34]. The third group received the
same PEMF signal as the second group, but with a five minute
on/off regimen; these animals were placed in the coil-covered
cage for four hours per day to ensure that the total amount of
PEMF time was the same in each animal. The fourth group
also received the basic PEMF signal, but a custom-made
amplifier added random noise of 50–150 kHz over the basic
stimulus. Animals were treated with this latter signal for
two hours per day.
A fifth group received a PEMF signal that was not charac-
terised by pulse bursts as in the other treatment groups, but
consisted of quasi-rectangular single pulses of 1 G given at
7.5 Hz with a pulse duration of 0.3 ms. These animals were
treated for two hours per day.
In vivo microCT scans were made at zero, three and
six weeks after OVX. Using isoflurane (3%) rats were anaes-
thetised and the right hind leg was scanned (voltage of 60 kV,
current of 167 μA, 0.5-mm aluminium filter, 196° with a
rotation step of 1°) (SkyScan 1076Microtomograph, Kontich,
Belgium). Then 3D reconstructions with an isotropic voxel
size of 18 μmwere made of the proximal tibia and the mid-
diaphysis (Nrecon software version 1.5, SkyScan) (Fig. 2).
The proximal metaphysis mainly consists of cancellous bone.
Fig. 1 Rat receiving systemic PEMF treatment. The cage is sur-
rounded by coils. The custom-made generator can produce different
electromagnetic signals
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A length of 5.4 mm was selected of which the epiphysis was
manually deselected. The mid-diaphysis consists of cortical
bone and the region of interest was selected 9 mm distal
from the epiphysis and continued to 3.6 mm more distally.
Using a local threshold, bone was separated from non-
osseous structures, which resulted in binary data sets [35].
After automatic separation between trabecular and cortical bone
using in-house software bone parameters were determined (3D-
calculator, SkyScan) [36]. On the metaphyseal region of inter-
est, volume fraction (BV/TV), connectivity density (Conn/
TV), structure model index (SMI), in which an index of 3
indicates the presence of rods and an index of 0 indicates the
presence of plates, and 3D trabecular thickness (TbTh) were
determined. On the diaphyseal region of interest, cortical
volume (CtV) and cortical thickness (CtTh) were determined.
Differences between means of the different treatment
groups were statistically analysed using one-way analysis
of variance (ANOVA) with a Tukey’s multiple comparison
test for each time point separately (GraphPad Software, San
Diego, CA, USA).
Results
All surgical procedures were performed without complica-
tions. At the start of the study the average body weight of
the rats was 224.6 g (SD 5.3). No period of weight loss was
observed during the experimental period. The average weight
gain was 57.6 g (SD 8.7) and there was no difference in weight
gain between controls and any of the PEMF-treated groups.
In non-treated control animals BV/TV decreased from
31.7% (SD 4.8) at week zero to 24.2% (SD 4.1) and
19.7% (SD 3.5) at weeks three and six, respectively, as a
consequence of OVX (Table 1). Morphometric parameters
changed concomitantly, especially between weeks zero and
three, with a decrease in mean TbTh, a decrease in Conn/TV
and a structural change of trabeculae towards more rod-like
structures, as apparent from an increase in SMI (Table 1). CtV
increased from 12.3 (SD 0.23) mm3 at week zero to 12.9 (SD
0.23) mm3 and 13.3 (SD 0.43) mm3 at weeks three and six,
respectively. Mean CtTh also increased during this period.
None of the PEMF-treated groups showed a significant
difference in BV/TVor CtV compared with the control group
at any time point (Fig. 3). The morphometric parameters also
showed no significant differences compared with control ani-
mals. There were no indications to speculate the presence of
any non-significant trend in the follow-up outcome variables.
Discussion
In this study we examined the effects of PEMF on bone
changes in the cancellous and cortical bone during a six-week
follow-up period. Althoughwe used in vivomicroCTscanning,
which is a very sensitive analysis method, we were unable to
reproduce the strong beneficial effects of PEMF on osteoporo-
sis in ovariectomised rats as shown by others [12, 25, 26].
In this study four treatment protocols were used. Three of
these protocols were based on a commercially available
PEMF generator used for the treatment of non-unions. The
fourth signal was developed as a single burst in order to be
more comparable with the study of Chang and Chang [12]. In
the study of Chang and Chang it was shown that PEMF
prevented the trabecular bone loss induced by ovariectomy.
Although one of the groups received PEMF with character-
istics based on their signal, some differences in the experi-
mental set-up still remain. Our signal had an electromagnetic
current of 1 G instead of 4–8 G in the signal of Chang and
Chang. Furthermore, they treated the rats for eight hours per
day instead of two hours as used in our study. To examine
whether longer exposure to PEMFwould prevent further bone
loss in our experimental set-up, we extended the experiment
for an additional six weeks and treated the same animals for
eight hours per day. However, trabecular bone loss was com-
parable to non-treated controls and no preventive effects of
longer treatment could be found.
Fig. 2 Three-dimensional reconstruction of a microCT scan of the
proximal tibia. The regions of interest in the metaphysis and diaphysis
are indicated
Table 1 Bone changes in the proximal tibia of ovariectomised non-
treated control animals. Mean values with standard deviations are
given (n04)
Week 0 Week 3 Week 6
Volume fraction (%) 31.7 (4.8) 24.2 (4.1) 19.7 (3.5)
Trabecular
thickness (μm)
127.3 (5.6) 125.0 (3.7) 118.9 (2.2)
Connectivity
density (/mm3)
78.7 (14.5) 47.5 (15.6) 38.9 (12.9)
Structural model index 1.7 (0.19) 2.1 (0.15) 2.2 (0.09)
Cortical volume (mm3) 12.3 (0.23) 12.9 (0.36) 13.3 (0.43)
Cortical thickness (μm) 608.2 (9.4) 625.6 (4.0) 646.4 (15.4)
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In a more recent article PEMF, consisting of pulse bursts
with an electromagnetic current of 9.6 G, were applied to
ovariectomised rats during day time or night time [25]. In
both groups PEMF treatment resulted in an increase in BMD
and increased trabecular bone mass compared to ovariectom-
ised controls. It was shown that treatment during daytime was
more efficient than an overnight treatment. No effect on
cortical bone was found. In another study in which ovariec-
tomised rats were exposed to a 50-Hz sinusoidal waveform of
10 G an increase in cortical volume of 71% compared to
non-treated controls was found [26]. One study has been
published in which a negative finding is described. In that
study 24 hours per day of systemic PEMF with a maximum
magnetic field of 15 G did not result in an increased bone
mineral content after eight months of treatment [27].
Apart from differences in the characteristics of PEMF treat-
ment used in each study, the ages of the animals also vary. In
the studies that did find a positive effect of PEMF, eight to 13-
week-old rats were used [12, 25, 26]. In our study 20-week-old
rats were used and in the study of Takayama et al. five-month-
old rats were used [27]. Rats younger than 20 weeks of age
undergo extensive longitudinal growth, which probably affects
the outcomes. For osteoporotic research it might be preferable
to use skeletally mature animals, so that the results are easier to
interpret in relation to the clinical situation.
Use of in vivo microCT scanning allows one to detect very
small changes, because longitudinal data are collected. In the
control group we observed an absolute decline in BV/TV of
7.5% (SD 1.63) at three weeks (Table 1). At a power of 0.8, an
α of 0.05 and with four animals per group, this gives a
detectable alternative of 2.5% when comparing means of
two groups. Thus, we would have been able to detect an effect
of PEMF if the treatment had decreased trabecular bone loss to
5% or less compared to controls. Similar calculations for
changes in CtV show that we would have been able to detect
an effect of PEMF when cortical thickening was prevented by
0.25mm3 or less given that control animals gain 0.6 (SD 0.17)
mm3 of cortical bone in three weeks. In our opinion this is
sufficient power because effects smaller than this would most
likely not be of clinical significance. With this power we were
also able to detect differences when bone changes at the
magnitude of other studies were found.
In a clinical trial it was shown that by treating the proximal
forearm of osteoporosis-prone women, an increase in BMD
was induced at the distal radius of the treated side and also at
the contralateral side, which suggests PEMF induced a sys-
temic effect [23]. It is peculiar that this research and the strong
beneficial effects in earlier animal experiments have not led to
a range of clinical trials in which the effect of this safe and
non-invasive intervention on bone mass is further examined.
For many years attempts have been made to perform a pro-
spective randomised controlled trial to determine the effect of
PEMF on non-unions, but due to a lack of sufficient numbers
for adequate statistical power this has never been achieved
[17, 20, 37, 38]. Obtaining sufficient numbers would not be a
problem in a clinical trial examining the effects of PEMF on
bone mass in healthy or osteoporotic individuals. Because
PEMF does not induce any side effects and the exact exper-
imental set-up is important for the outcome, it would be more
logical and favourable to perform future studies on the effect
of PEMF on bone in humans and not in animals. With the use
of non-invasive techniques such as dual-energy X-ray absorp-
tiometry (DXA) scanning and peripheral microCT scanning
the role of PEMF in osteoporosis could be determined with
certainty.
In this study we could not demonstrate a positive effect of
PEMF on the bone architecture in a ovariectomised rat
model of osteoporosis. This is in accordance with earlier
published work. However, because there are studies that did
find strong effects, it might be that PEMF are very effective
under the right circumstances. It might therefore be more
practicable to examine the effects of PEMF on bone mass
directly in humans such that translation from small animal
experiments is not an issue. However, the results obtained in
our study do not substantiate a potential role for the use of
PEMF in post-menopausal osteoporosis.
Fig. 3 Trabecular volume fraction and cortical volume in the tibia of ovariectomised rats that received PEMF treatment (n04) or received no
treatment (controls, n04). Data are mean values and standard deviations
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